A few key slides - let's see who can do the math on this and come to the same conclusions I have (AU, US, EU discussions already underway, moving towards key partnership(S) and human ethics approval. Many excited parties.
1) Mouse model results are BEFORE refinements to dosing regimen, and yet the results are already outstanding.
2) RAC have already shopped these results around. The team is not idle on progressing commercialisation and know these deals take 12-18 months to negotiate.
3) RAC IMO is the best kept secret on the ASX - but with MAJOR journal publication incoming, how much longer will it stay under the radar?
4) This is the continuation of the team's promise to deliver news this quarter, and we are seeing transparency and consistency in action.
5) The EM AML pathway is extremely valuable and fast to market. It is only one of many shots on goal for Zantrene, and we haven't even touched on cardio yet. The inferred market value is extremely hard to calculate. This will change over the next 10 months to something more tangible.
Congratulations to the Race team on another milestone met.
Ann: Zantrene highly effective in EMD AML Mouse Model, page-25
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |